How to buy bluebird bio stock | 54.55

bluebird bio, Inc is a biotechnology business based in the US. bluebird bio shares (BLUE) are listed on the NASDAQ and all prices are listed in US Dollars. bluebird bio employs 1,167 staff and has a trailing 12-month revenue of around USD$239.7 million.

How to buy shares in bluebird bio

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for bluebird bio. Find the stock by name or ticker symbol: BLUE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until bluebird bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$54.55, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of bluebird bio, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of bluebird bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted bluebird bio's share price?

Since the stock market crash in March caused by coronavirus, bluebird bio's share price has had significant negative movement.

Its last market close was USD$54.55, which is 31.98% down on its pre-crash value of USD$80.2 and 40.05% up on the lowest point reached during the March crash when the shares fell as low as USD$38.95.

If you had bought USD$1,000 worth of bluebird bio shares at the start of February 2020, those shares would have been worth USD$543.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$624.60.

bluebird bio share price

Use our graph to track the performance of BLUE stocks over time.

bluebird bio shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$54.55
52-week range	USD$38.95 - USD$99.36
50-day moving average	USD$55.9997
200-day moving average	USD$59.0675
Wall St. target price	USD$103.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-12.004

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy bluebird bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of bluebird bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

bluebird bio price performance over time

Historical closes compared with the close of $54.55 from 2020-10-19

1 week (2020-10-23)	-1.76%
1 month (2020-09-30)	1.11%
3 months (2020-07-30)	-11.00%
6 months (2020-04-30)	1.24%

1 year (2019-10-30)	-34.43%
2 years (2018-10-30)	-50.80%
3 years (2017-10-30)	-61.48%
5 years (2015-10-30)	-29.28%

Is bluebird bio under- or over-valued?

Valuing bluebird bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of bluebird bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

bluebird bio's PEG ratio

bluebird bio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into bluebird bio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

bluebird bio financials

Revenue TTM	USD$239.7 million
Gross profit TTM	USD$-540,717,000
Return on assets TTM	-20.36%
Return on equity TTM	-39.38%
Profit margin	-272.66%
Book value	$25.41
Market capitalisation	USD$3.6 billion

TTM: trailing 12 months

Shorting bluebird bio shares

There are currently 6.1 million bluebird bio shares held short by investors – that's known as bluebird bio's "short interest". This figure is 0.7% down from 6.2 million last month.

There are a few different ways that this level of interest in shorting bluebird bio shares can be evaluated.

bluebird bio's "short interest ratio" (SIR)

bluebird bio's "short interest ratio" (SIR) is the quantity of bluebird bio shares currently shorted divided by the average quantity of bluebird bio shares traded daily (recently around 699204). bluebird bio's SIR currently stands at 8.75. In other words for every 100,000 bluebird bio shares traded daily on the market, roughly 8750 shares are currently held short.

However bluebird bio's short interest can also be evaluated against the total number of bluebird bio shares, or, against the total number of tradable bluebird bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case bluebird bio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 bluebird bio shares in existence, roughly 90 shares are currently held short) or 0.1345% of the tradable shares (for every 100,000 tradable bluebird bio shares, roughly 135 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against bluebird bio.

Find out more about how you can short bluebird bio stock.

bluebird bio share dividends

We're not expecting bluebird bio to pay a dividend over the next 12 months.

bluebird bio share price volatility

Over the last 12 months, bluebird bio's shares have ranged in value from as little as $38.95 up to $99.36. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while bluebird bio's is 2.0927. This would suggest that bluebird bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

bluebird bio overview

bluebird bio, Inc., a biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of bluebird bio is owned by insiders or institutions?

  Currently 0.618% of bluebird bio shares are held by insiders and 109.96% by institutions.

• How many people work for bluebird bio?

  Latest data suggests 1,167 work at bluebird bio.

• When does the fiscal year end for bluebird bio?

  bluebird bio's fiscal year ends in December.

• Where is bluebird bio based?

  bluebird bio's address is: 60 Binney Street, Cambridge, MA, United States, 02142

• What is bluebird bio's ISIN number?

  bluebird bio's international securities identification number is: US09609G1004

• What is bluebird bio's CUSIP number?

  bluebird bio's Committee on Uniform Securities Identification Procedures number is: 09609G100